Case number 1:22-cv-00181
Allergan USA, Inc. et al v. MSN Laboratories Private Limited et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Oct 12, 2023 | 9 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,229,627 B2. (Attachments: # 1 Final Judgment filed in Lead Civil Action 19-1727-RGA)(nms) (Entered: 10/12/2023) (0) |
| Mar 22, 2022 | 8 | Order (4) Docket Text: SO ORDERED Granting Stipulation and Proposed Order to Consolidate Cases and Modify Scheduling Order (D.I. 7 in 22-cv-182-RGA; D.I. 337 in 19-cv-1727-RGA; D.I. 7 in 22-cv-181-RGA). Signed by Judge Richard G. Andrews on 3/22/2022. Associated Cases: 1:19-cv-01727-RGA, 1:22-cv-00181-RGA, 1:22-cv-00182-RGA(nms) |
| Mar 21, 2022 | 7 | Stipulation (4) Docket Text: STIPULATION and [Proposed] Order to Consolidate Cases and Modify Scheduling Order by Allergan Holdings Unlimited Company, Allergan USA, Inc., Eden Biodesign, LLC. (Tigan, Jeremy) |
| Feb 16, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. Associated Cases: 1:22-cv-00181-RGA, 1:22-cv-00182-RGA (rjb) |
| Feb 10, 2022 | 6 | Main Document (2) Docket Text: Summons Issued with Magistrate Consent Notice attached as to MSN Laboratories Private Limited on 2/10/2022; MSN Pharmaceuticals Inc. on 2/10/2022. (Attachments: # (1) Summons Issued)(myr) |
| Feb 10, 2022 | 6 | Summons Issued (2) |
| Feb 9, 2022 | 1 | Main Document (9) Docket Text: COMPLAINT filed against MSN Laboratories Private Limited, MSN Pharmaceuticals Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3799734.) - filed by Allergan USA, Inc., Allergan Holdings Unlimited Company, Eden Biodesign, LLC. (Attachments: # (1) Exhibit A, # (2) Civil Cover Sheet)(myr) |
| Feb 9, 2022 | 1 | Exhibit A (24) |
| Feb 9, 2022 | 1 | Civil Cover Sheet (2) |
| Feb 9, 2022 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (myr) |
| Feb 9, 2022 | 3 | ANDA Form (1) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: N/A. Date of Expiration of Patent: March 14, 2033. 30 Month Stay Deadline: N/A (myr) |
| Feb 9, 2022 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,229,627 B1. (myr) |
| Feb 9, 2022 | 5 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent AbbVie Inc. for Allergan Holdings Unlimited Company, Allergan USA, Inc., Eden Biodesign, LLC filed by Allergan Holdings Unlimited Company, Allergan USA, Inc., Eden Biodesign, LLC. (myr) |
| Feb 9, 2022 | 1 | Complaint* (1) |
